Impacts of Durian Consumption on Human Microbiome and Metabolome in Healthy Staff Volunteers
NCT ID: NCT06194084
Last Updated: 2025-10-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
45 participants
INTERVENTIONAL
2023-02-01
2025-08-29
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Thermogenic Effect and Metabolic Responses of Durian
NCT06121817
Impacts of Fruit on the Gut Health and Human Health
NCT05063929
Blackcurrants Modify Gut Microbiota and Reduce Osteoporosis and CVD Risk
NCT04431960
The Prebiotic Effect of Daily Intake of Orange Juice Affects the Bioavailability of Flavanones?
NCT03032861
Effects of Cranberry Powder Supplements on Gut Microbiota Diversity and Metabolic Syndrome
NCT03754504
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The first outcomes of this study will provide insights into the interplay between durian consumption, gut microbiome, and host metabolome, as well as whether durian consumption can improve the clinical parameters (plasma glucose levels, lipid profiles and HbA1c levels) of healthy subjects. The interplay between diets, gut microbiome, host metabolome and genetic polymorphism data in healthy population will lay the groundwork to develop the precision nutrition strategy based on our regional food. These findings have potential to improve the health and well-being of the communities in our region.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Intervention - durian pulp.
Two-sequence of doses (100 g and 200 g) of durian pulp.
Two-sequence of durian pulp doses (100 g and 200 g)
Participants first go through an initial washout maintaining a low-fiber diet for 14 days. After washout, participants will be instructed to consume 100 grams of durian pulp every day following their breakfast or dinner for 1 week. Participants will then continue to consume 200 grams of durian pulp every day during the 2nd week of intervention and then will go through another washout for 2 weeks.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Two-sequence of durian pulp doses (100 g and 200 g)
Participants first go through an initial washout maintaining a low-fiber diet for 14 days. After washout, participants will be instructed to consume 100 grams of durian pulp every day following their breakfast or dinner for 1 week. Participants will then continue to consume 200 grams of durian pulp every day during the 2nd week of intervention and then will go through another washout for 2 weeks.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Willing and able to provide written informed consent
3. Must be in generally good health with clinically insignificant screening results (Fasting plasma glucose level \& Lipid profile), as determined by the Investigator
4. Agrees to consume durian for 2 weeks
5. Agrees to maintain a low-fiber diet during the intervention
6. Have not received any antibiotics therapy, consumed prebiotics, probiotics, symbiotic /vitamin supplement, and/or TCM for at least 1 month before the start of the study
7. Have not received any medical treatment that would impact on intestinal microbiota at least 6 months before the start of the study or during the study
8. Recent COVID-19 vaccination received or infection with COVID-19 at least 2 months ago
Exclusion Criteria
2. Multiple food/drug allergies
3. Smoker
4. History or presence of current metabolic conditions and gastrointestinal diseases
5. Diagnosed with Inflammatory Bowel Disease (IBD) or significant liver enzyme abnormality
6. Presence of current haemorrhoids or piles causing rectal bleeding when passing stool
7. Pregnant, breastfeeding or intending to conceive during study period
21 Years
60 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Centre, Singapore
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jason YS CHAN, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
National Cancer Centre, Singapore
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
National Cancer Centre, Singapore
Singapore, , Singapore
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DURIOME
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.